DRUG
Cagrilintide B
Cagrilintide B will be administered subcutaneously.
A Research Study to Compare Blood Levels of Two Different Versions of Cagrilintide in Adults With Excess Body Weight
Status
Active, not recruiting
Phase
Phase 1
Enrollment
50
Locations
1
Results
Not posted
Publications
0
Study summary
What the protocol is testing.
The purpose of this clinical study is to compare 2 different versions cagrilintide and see how these work in people living with excess body weight. Participant will get either cagrilintide B or cagrilintide D injections. Which treatment participant will get is decided by chance. Participant will be in this clinical study for about 14 weeks.
Interventions
Treatment arms and agents.
DRUG
Cagrilintide D
Cagrilintide D will be administered subcutaneously.
Timeline
From registration to results.
First posted
May 22, 2026
Study start
May 20, 2026
Primary completion
Sep 3, 2026
Study completion
Sep 3, 2026
Results posted
Not reported
Registry updated
Jul 9, 2026
Outcomes
What the study measures.
Primary outcomes
AUCss: area under the total cagrilintide concentration-time curve at steady state after 5th dosing of cagrilintide
Time frame · From Pre-dose at Day 29 to Day 36
Measured as hour\*nanomole per liter (h\*nmol/L).
Cmax,ss: maximum observed concentration of total cagrilintide at steady state after 5th dosing of cagrilintide
Time frame · From Pre-dose at Day 29 to Day 36
Measured as nanomole per liter (nmol/L).
Secondary outcomes
AUCss: area under the total cagrilintide concentration-time curve at steady state after 4th dosing of cagrilintide
Time frame · From Pre-dose at Day 22 to Day 29
Measured as h\*nmol/L.
Cmax,ss: maximum observed concentration of total cagrilintide at steady state after 4th dosing of cagrilintide
Time frame · From Pre-dose at Day 22 to Day 29
Measured as nmol/L.
AUCss: area under the total cagrilintide concentration-time curve at steady state after 1st dosing of cagrilintide
Time frame · From Pre-dose at Day 1 to Day 8
Measured as h\*nmol/L.
Cmax,ss: maximum observed concentration of total cagrilintide at steady state after 1st dosing of cagrilintide
Time frame · From Pre-dose at Day 1 to Day 8
Measured as nmol/L.
Eligibility
Who can take part.
- Minimum age
- 18 Years
- Maximum age
- 64 Years
- Sex
- ALL
- Healthy volunteers
- No
Key Inclusion Criteria: * Age 18-64 years (both inclusive) at the time of signing informed consent. * Male or female (sex assigned at birth). * Body mass index (BMI) between 27.0 and 34.9 kilogram per meter square (kg/m\^2) (both inclusive) at screening. Overweight should be due to excess adipose tissue, as judged by the investigator. * Considered eligible based on the medical history, physical examination, and the results of vital signs, electrocardiogram (ECG), and clinical laboratory tests performed during the screening visit, as judged by the investigator. Key Exclusion Criteria: * Previous dosing of marketed or non-marketed amylin-agonists (a). * Any condition, unwillingness or inability which in the investigator's opinion might jeopardise the participant's safety or compliance with the protocol (a). 1. As declared by the participant, reported in the medical records or at the investigator's discretion.
Study locations
1 registered sites.
United States. Showing up to 24 locations stored in the fast local snapshot.
Celerion, Phoenix
Tempe, Arizona, United States
Publications
Results and literature.
No PMID-linked publications were present in this registry snapshot.
Related trials
More studies on Cagrilintide.
NCT IDStudyPhase / statusEnrollmentUpdated
A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
Novo Nordisk · Obesity · Type 2 Diabetes
Phase 3
Recruiting
2,500
2026-07
A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term
Novo Nordisk · Obesity
Phase 3
Active, not recruiting
609
2026-07
A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight
Novo Nordisk · Obesity
Phase 3
Active, not recruiting
3,400
2026-07
REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels
Novo Nordisk · Cardiovascular Disease
Phase 3
Active, not recruiting
7,101
2026-07
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both
Novo Nordisk · Diabetes Mellitus, Type 2
Phase 3
Completed
1,023
2026-07
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
Novo Nordisk · Overweight · Obesity
Phase 3
Recruiting
460
2026-07
A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes
Novo Nordisk · Diabetes Mellitus, Type 2
Phase 2
Withdrawn
0
2026-07
A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight
Novo Nordisk · Overweight · Obesity
Phase 3
Withdrawn
0
2026-07
Related PeptideStat pages
Put the record in context.
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.